emerg
new
resist
mechan
failur
classic
antibiot
clinic
decreas
develop
antibiot
industri
challeng
lead
us
consid
new
strategi
treatment
infecti
diseas
inde
recent
year
controversi
intensifi
strain
resist
carbapenem
andor
colistin
variou
therapeut
solut
use
overcom
administr
last
line
antibiot
context
drug
repurpos
consist
use
nonantibiot
compound
treat
multidrug
resist
bacteria
mdr
encourag
review
first
report
may
led
drug
repurpos
main
definit
advantag
drawback
summar
three
major
method
describ
phenotyp
comput
serendip
second
time
focu
current
knowledg
drug
repurpos
carbapenem
colistinresist
bacteria
differ
studi
describ
repurpos
compound
test
gramneg
bacteria
furthermor
show
drug
combin
therapi
increas
success
drug
repurpos
strategi
conclus
discuss
pharmaceut
industri
littl
interest
reprofil
drug
due
lack
profit
also
consid
clinician
might
think
indic
uncommon
biologist
treat
mdr
bacteri
infect
avoid
therapeut
impass
nowaday
despit
recent
scientif
progress
infecti
diseas
must
alway
taken
consider
world
health
organ
close
examin
concern
order
effect
health
system
world
health
organ
year
confront
end
golden
age
antibiot
discoveri
antimicrobi
substanc
exist
year
gould
due
signific
progress
larg
contribut
reduc
number
death
infecti
diseas
pharmaceut
compani
develop
decreas
interest
drug
conli
johnston
addit
use
antibiot
emerg
resist
inevit
intrins
link
mohr
although
new
phenomenon
natur
one
analysi
warn
seriou
situat
impact
natur
spread
global
antimicrobi
resist
global
antimicrobi
resist
surveil
system
report
earli
implement
resist
bacteria
found
everi
kind
environ
water
anim
human
plant
food
rolain
zenati
et
al
bachiri
et
al
tafoukt
et
al
inappropri
use
antimicrobi
agent
spread
antibacteri
resist
among
factor
lead
high
rate
resist
clinic
anim
even
environment
isol
roca
et
al
bassetti
et
al
partli
drug
pressur
resist
occur
easili
affect
type
antibiot
lastlin
antibiot
use
human
medicin
drug
resist
bacteri
infect
biswa
et
al
recent
year
seen
increas
use
carbapenem
result
increas
carbapenem
resist
gramneg
bacteria
gnb
dien
rolain
exampl
monaco
et
al
show
itali
among
clinic
strain
isol
novemb
april
klebsiella
pneumonia
kpc
enzym
carbapenemas
resist
colistin
monaco
et
al
although
situat
report
colistin
olaitan
et
al
receiv
attent
lastlin
treatment
may
longer
effect
increas
risk
spread
infect
biswa
et
al
combat
frequent
epidem
challeng
rapid
spread
new
altern
last
resort
treatment
must
consid
avoid
treatment
failur
result
altern
antibiot
treat
resist
germ
prioriti
bassetti
et
al
use
old
drug
solut
like
forgotten
antibiot
polymyxin
fosfomycin
minocyclin
mecillinam
still
use
clinic
set
cassir
et
al
also
renew
interest
antibiot
combin
circumv
resist
lenhard
et
al
exampl
synergist
activ
sulfonamideassoci
colistin
evalu
colistinresist
clinic
bacteria
okdah
et
al
non
antibiot
solut
also
consid
altern
therapeut
manag
infect
aslam
et
al
variou
studi
show
clostridium
difficil
inhibit
use
bacteriophag
sever
ongo
trial
use
antimicrobi
peptid
altern
prevent
treatment
futur
aslam
et
al
fight
treat
multidrug
resist
mdr
infect
must
also
includ
chang
mental
rolain
baquero
denounc
fact
societi
accept
use
toxic
effect
antibiot
treatment
lifethreaten
infect
hand
societi
toler
potenti
toxic
drug
anticanc
progress
medicin
manag
advers
reaction
improv
monitor
antibiot
concentr
old
drug
dosag
reject
due
advers
effect
reconsid
rolain
baquero
way
one
promis
altern
review
focus
drug
repurpos
also
call
reposit
mercorelli
et
al
therapeut
shift
subject
sever
studi
differ
patholog
includ
cancer
sleir
et
al
heart
diseas
alzheim
diseas
kim
depress
ebada
infectiolog
repurpos
studi
carri
torr
et
al
soo
et
al
dangelo
et
al
zheng
et
al
et
al
gener
common
bacteria
first
test
risk
therapeut
deadlock
review
focus
drug
repurpos
test
mdr
bacteria
seem
import
precis
resist
rare
cross
molecul
activ
specif
speci
compound
potenti
activ
regardless
resist
mechan
molecul
affect
new
target
gener
independ
antibiot
target
see
ciclopirox
carlsonban
et
al
gallium
goss
et
al
zidovudin
elwel
et
al
therefor
expand
scope
combin
test
sensit
gnb
minocyclin
polymyxin
b
test
nonantibiot
drug
offer
diversifi
still
exploit
field
possibl
carbapenem
colistinresist
isol
articl
publish
specif
strive
synthes
aim
thu
identifi
innov
therapeut
strategi
bacteria
costeffect
effici
way
review
defin
drug
repurpos
characterist
make
inventori
alreadi
publish
drug
reus
gener
particular
address
problem
carbapenem
colistinresist
bacteria
final
see
prospect
exist
therapeut
strategi
drug
class
assign
molecul
describ
group
similari
togeth
drug
therapeut
use
biochem
mechan
way
action
chemic
structur
defin
waksman
antibiot
chemic
substanc
produc
microorgan
capac
inhibit
growth
even
destroy
bacteria
microorgan
mohr
current
trend
therefor
seem
move
away
definit
inde
recent
year
drug
reposit
seem
promis
field
drug
discoveri
identifi
new
therapeut
opportun
exist
drug
doan
et
al
common
idea
acceler
discoveri
new
treatment
use
old
drug
could
potenti
treat
diseas
treatment
use
longer
work
longer
therapeut
solut
must
use
langedijk
et
al
sir
jame
black
pharmacologist
nobel
laureat
said
fruit
basi
discoveri
new
drug
start
old
drug
chen
et
al
could
help
overcom
initi
bottleneck
drug
develop
process
may
therefor
better
compromis
risk
reward
approach
drug
develop
ashburn
thor
drug
repurpos
present
real
econom
advantag
studi
structur
pharmacolog
properti
bioavail
safeti
profil
exampl
alreadi
conduct
drug
possibl
skip
preclin
trial
toxic
pharmacokinet
alreadi
known
certain
hindsight
taken
sever
year
drug
move
directli
phase
test
effect
mercorelli
et
al
repurpos
drug
offer
new
pathway
target
studi
new
perspect
cure
diseas
mani
antibiot
alreadi
affect
dna
membran
protein
translat
pathway
essenti
bacteri
growth
remain
avail
activ
molecul
assimil
pathway
essenti
compound
like
sugar
amino
acid
combin
strategi
reduc
resist
use
achiev
sever
target
could
affect
bacteri
metabol
mercorelli
et
al
zheng
et
al
moreov
method
favor
academ
small
laboratori
disinterest
pharmaceut
industri
without
patent
industri
see
fruit
interest
rapid
emerg
resist
fernand
marten
narrow
spectrum
activ
zheng
et
al
hand
solut
total
miracul
drug
repurpos
work
time
due
high
minim
inhibitori
concentr
mic
mercorelli
et
al
inconsist
plasma
concentr
toler
human
dose
test
new
indic
import
lead
human
toxic
zheng
et
al
societi
fear
rolain
baquero
concern
galen
optim
formul
also
foreseen
physicochem
incompat
observ
consid
innov
strategi
doan
et
al
three
major
method
lead
drug
repurpos
shown
figur
first
phenotyp
assay
perform
high
throughput
screen
commerci
public
pharmaceut
compound
librari
jung
et
al
kim
assay
consist
classic
broth
microdilut
identifi
hit
torr
et
al
antibacteri
activ
found
mic
assay
perform
confirm
result
accord
clsi
guidelin
sun
et
al
compar
method
phenotyp
test
advantag
highli
physiolog
relev
effect
observ
directli
bacteria
zheng
et
al
advanc
genom
bioinformat
modifi
drug
reposit
approach
consist
silico
structur
mechanismbas
assay
work
virtual
databas
made
possibl
prospect
develop
drug
databas
activ
exchang
inform
compound
collabor
network
abund
resourc
internet
hodo
et
al
new
calcul
tool
make
possibl
analys
differ
data
accumul
field
man
alon
studi
complex
ensur
understand
predict
molecul
gener
hypothes
biolog
mechan
hodo
et
al
limit
approach
pathway
target
data
must
alreadi
known
moreov
fals
posit
toxic
problemat
issu
found
identif
hit
mercorelli
et
al
howev
emerg
diseas
could
quick
way
find
effect
molecul
done
coronaviru
law
et
al
last
approach
random
discoveri
includ
type
configur
inde
side
effect
one
drug
one
diseas
may
effect
anoth
antidepress
bupropion
reorient
antitobacco
drug
hodo
et
al
mere
coincid
sulfamid
known
antibacteri
properti
final
also
employ
antidiabet
one
deuil
howev
unexpect
observ
could
also
potenti
identifi
informat
method
view
knowledg
compound
side
effect
hodo
et
al
despit
techniqu
molecul
identifi
must
go
step
clinic
evalu
studi
gener
screen
mdr
bacteria
ensur
broader
spectrum
action
hijazi
et
al
sometim
bacteria
tabl
seven
nonantibacteri
compound
inhibit
growth
acinetobact
baumannii
strain
resist
antibiot
includ
carbapenem
antineoplast
antirheumat
auranofin
antipsychot
fluspirilen
antiinflammatori
bay
alcohol
deterr
disulfiram
fivefluorouracil
seem
best
candid
repurpos
treat
mdr
clinic
baumannii
valu
mic
lower
standard
plasma
drug
concentr
level
human
suggest
possibl
use
without
major
advers
event
cheng
et
al
mechan
action
target
consid
object
escap
therapeut
drug
class
repurpos
molecul
use
studi
new
pathway
figur
antifung
agent
develop
nearli
forti
year
ago
ciclopirox
also
good
repurpos
criteria
shown
american
studi
conduct
carlsonban
et
al
due
excel
safeti
profil
alreadi
repurpos
variou
patholog
myeloma
antihuman
immunodefici
viru
drug
prevent
enzym
action
essenti
cellular
metabol
function
inhibit
avail
cofactor
activ
prove
mdr
e
coli
k
pneumonia
baumannii
strain
demonstr
novel
mechan
action
ciclopirox
affect
galactos
lp
salvag
pathway
carlsonban
et
al
addit
bacteri
activ
gallium
known
year
first
use
anticanc
agent
due
chemic
similar
iron
gallium
inhibit
ferric
redox
reaction
pathway
bacteri
growth
matter
broad
spectrum
activ
particular
mdr
eskap
pathogen
rangelvega
et
al
hijazi
et
al
fact
phase
trial
cystic
fibrosi
patient
assess
activ
gallium
suggest
safeti
figur
annual
number
public
pubm
search
engin
drug
repurpos
keyword
frontier
cellular
infect
microbiolog
wwwfrontiersinorg
efficaci
human
infect
goss
et
al
repres
potenti
promis
target
control
infecti
germ
notic
pharmaceut
class
involv
anticanc
antiinflammatori
also
antiparasit
drug
et
al
studi
stoke
stoke
et
al
previou
year
show
pentamidin
effect
polymyxin
resist
strain
antiprotozo
agent
usual
effect
trypanosomiasi
leishmaniasi
fungal
infect
test
enterobacteriacea
k
pneumonia
e
coli
enterobact
cloaca
pentamidin
bactericid
strain
carri
carbapenemas
show
colistin
resist
moreov
effect
potenti
activ
antibiot
due
synergist
activ
rifampicin
aminoglycosid
e
cloaca
rifampicin
combin
effect
strain
test
cebrerocangueiro
et
al
context
drug
reprofil
variou
studi
identifi
antiretrovir
zidovudin
also
call
azidothymidin
azt
activ
molecul
resist
enterobacteriacea
et
al
peyclit
et
al
interest
drug
repurpos
mdr
enterobacteri
infect
reviv
forgotten
antibacteri
properti
drug
mention
first
time
elwel
et
al
seri
enterobacteriacea
differ
colistin
resist
profil
gene
mgrb
pmrb
mutat
antibacteri
action
confirm
mic
rang
pharmacokinet
data
show
azt
concentr
found
would
compat
plasma
concentr
obtain
dose
use
human
medicin
peyclit
et
al
due
rel
rapid
mutat
frequenc
et
al
resist
strain
alreadi
report
lewin
et
al
would
appear
zidovudin
suitabl
use
combin
inde
zidovudin
test
variou
associ
antibiot
differ
class
lewin
et
al
mascellino
et
al
recent
articl
checkerboard
analysi
colistin
show
synergist
activ
extend
spectrum
esbl
e
coli
esbl
k
pneumonia
produc
strain
colistin
resist
e
coli
bactericid
combin
activ
colistin
improv
could
reduc
dose
colistin
better
effect
patent
hu
coat
enrol
phase
clinic
trial
result
show
associ
bactericid
activ
plasma
concentr
posit
strain
well
toler
healthi
volunt
involv
studi
loos
et
al
human
studi
undertaken
confirm
result
confirm
azt
recoveri
therapi
mdr
bacteria
thu
help
clinician
avoid
therapeut
impass
final
order
anticip
emerg
resist
bacteria
molecul
signific
advantag
use
alon
focus
multipl
target
thu
erad
infect
quickli
possibl
find
posit
respons
new
use
suffici
meet
criteria
efficaci
safeti
pharmacodynam
nontox
combin
studi
anoth
drug
may
consid
order
use
effect
drug
combin
consist
associ
two
drug
order
enhanc
efficaci
therapeut
strategi
increas
chanc
clinic
applic
broaden
spectrum
activ
use
antibiot
exampl
seriou
infect
requir
urgent
effect
treatment
zheng
et
al
use
two
drug
impact
differ
target
increas
impair
microbi
function
reduc
risk
resist
emerg
zheng
et
al
main
goal
drug
associ
produc
synergist
effect
effect
produc
combin
greater
achiev
drug
use
alon
moreov
one
compound
low
activ
anoth
potenti
increas
reduc
concentr
individu
molecul
therefor
use
lower
dose
real
advantag
one
know
toxic
certain
drug
sun
et
al
zheng
et
al
sun
et
al
show
use
drug
combin
reduc
toxic
increas
activ
compar
singl
therapi
cytotox
proven
allow
use
drug
human
medicin
conceiv
sun
et
al
research
drug
repurpos
combin
known
antibiot
carbapenem
andor
colistinresist
bacteria
mainli
conduct
associ
polymyxin
drug
tabl
niclosamid
anthelmint
drug
known
activ
tapeworm
seem
interact
neg
charg
outer
membran
colistinresist
strain
lead
synergist
effect
colistin
effect
observ
strain
colistinresist
baumannii
pmrb
alter
colistinresist
k
pneumonia
mgrb
pmrb
alter
ayerbealgaba
et
al
colistin
combin
therapi
select
estrogen
receptor
modul
serm
tamoxifen
raloxifen
toremifen
also
exhibit
good
activ
polymyxinresist
p
aeruginosa
k
pneumonia
baumannii
test
invitro
concentr
could
achiev
human
concentr
hussein
et
al
schneider
et
al
fluspirilen
bay
shown
promis
result
resensit
resist
baumannii
overcom
colistin
resist
cheng
et
al
regard
polymyxin
b
synergist
activ
mitotan
antineoplast
approv
carcinoma
treatment
studi
invitro
strain
includ
carbapenem
polymyxinresist
gnb
test
also
carri
infect
mous
burn
wound
led
promis
result
treatment
type
infect
tran
et
al
use
knowledg
mechan
action
approach
also
test
channelblock
molecul
inde
efflux
pump
inhibitor
effect
bacteria
alon
combin
antibiot
demonstr
restor
activ
effect
less
strong
neurolept
prochlorperazin
chlorpromazin
promazin
associ
meropenem
appear
effect
mdr
baumannii
yang
chua
otto
et
al
show
potenti
efficaci
drug
includ
antidepress
amitriptylin
imipramin
sertralin
antipsychot
chlorpromazin
clonazepam
haloperidol
levopromazin
polymyxin
b
test
gnb
display
variou
resist
mechan
includ
carbapenemas
otto
et
al
sertralin
chlorpromazin
levopromazin
synerg
effect
polymyxin
b
baumannii
e
coli
k
pneumonia
isol
among
nonantibiot
spironolacton
good
efficaci
e
coli
isol
show
nontox
level
minimum
concentr
synergi
polymyxin
b
otto
et
al
find
show
nonantibiot
molecul
effect
combin
studi
need
pursu
develop
associ
effect
concentr
clinic
toler
otto
et
al
although
natur
compound
fdaapprov
may
also
part
process
compound
use
anoth
known
properti
stilben
polyphenol
resveratrol
produc
variou
plant
grape
blueberri
known
variou
antioxid
properti
chemoprevent
activ
bark
nauclea
pobeguinii
cameroonian
research
found
compound
test
gnb
mdr
phenotyp
activ
alon
synergi
streptomycin
ciprofloxacin
seukep
et
al
rossolini
et
al
demonstr
activ
resveratrol
antimicrobi
agent
combin
colistin
panel
colistinresist
chromosom
plasmid
resist
gnb
cannatelli
et
al
resveratrol
seem
potenti
colistin
activ
thu
make
possibl
restor
action
among
differ
speci
resist
pathway
thu
anoth
natur
compound
pterostilben
deriv
blueberri
grape
known
anticanc
antiinflammatori
antioxid
effect
appear
enhanc
polymyxin
activ
vitro
vivo
zhou
et
al
demonstr
synergist
figur
proceed
dtr
difficulttotreat
resist
bacteria
frontier
cellular
infect
microbiolog
wwwfrontiersinorg
effect
colistin
polymyxin
b
posit
strain
reduc
mic
polymyxin
b
zhou
et
al
pterostilben
could
therefor
affect
function
restor
antibacteri
activ
polymyxin
b
resist
isol
probabl
safe
human
clinic
practic
possibl
exert
select
pressur
associ
current
atb
therefor
consid
good
candid
drug
repurpos
zhou
et
al
lastli
eugenol
phenylpropanoid
present
essenti
oil
mani
plant
thirteen
anim
e
coli
strain
colistin
resist
subject
mic
time
kill
checkerboard
assay
evalu
combin
colistin
eugenol
observ
gene
express
regul
eugenol
suggest
possibl
bind
eugenol
protein
molecul
still
test
vitro
clinic
trial
none
yet
receiv
new
indic
mdr
infect
treatment
howev
research
drug
repurpos
gain
new
dynam
refer
number
annual
public
recent
year
figur
conclus
review
therefor
address
two
main
aspect
emerg
drug
repurpos
strategi
resist
lastlin
antibiot
carbapenem
colistin
new
econom
model
consid
antibiot
develop
industri
seem
interest
new
strategi
zheng
et
al
inde
antibiot
part
chronic
treatment
strategi
could
econom
attract
conli
johnston
disinterest
antibiot
research
reflect
absenc
program
futur
develop
major
pharmaceut
compani
spellberg
et
al
startup
small
compani
hand
see
interest
take
back
antibiot
fail
clinic
phase
exampl
believ
differ
drug
develop
strategi
requir
mani
benefit
cover
cost
compar
multin
pharmaceut
compani
fernand
marten
howev
phase
clinic
trial
new
repurpos
drug
remain
expens
estim
million
million
usd
azvolinski
budget
work
favor
small
firm
question
treat
bacteri
resist
one
answer
found
futur
offer
us
new
possibl
variou
strategi
consid
treatment
use
fecal
microbiota
davido
et
al
antimicrobi
peptid
hashemi
et
al
bacteriophag
parmar
et
al
streptomyc
sp
present
alkalin
soil
ireland
spotlight
recent
inhibit
growth
mdr
bacteria
terra
et
al
remind
flem
discoveri
addit
discoveri
studi
system
may
suggest
may
ultim
weapon
fight
infecti
diseas
thu
control
antibiot
resist
doerfling
et
al
question
drug
repurpos
remain
rather
wide
although
seem
better
solut
drug
combin
also
lead
advers
interact
first
toxic
side
effect
increas
concern
compound
galen
physicochem
interact
differ
stabil
solubl
conserv
result
combin
two
molecul
make
incompat
formul
becom
complic
sun
et
al
hand
must
chang
vision
drug
belong
one
box
clinician
may
difficulti
understand
biologist
recommend
use
anticanc
antiinflammatori
drug
treat
cystic
fibrosi
patient
bacteremia
rather
last
resort
antibiot
alway
use
commun
sens
remain
essenti
health
profession
clinic
studi
prove
activ
critic
howev
current
knowledg
drug
repurpos
antibacteri
agent
problemat
find
altern
therapeut
situat
screen
nonantibiot
la
cart
way
issu
figur
area
person
medicin
could
imagin
person
antibiot
suscept
test
case
infect
caus
highli
resist
bacterium
lastlin
antibiot
test
appear
insuffici
success
treat
patient
test
nonantibiot
drug
potenti
activ
pathogen
alon
combin
antibiot
could
help
clinician
use
drug
previous
report
kadri
et
al
difficulttothreat
bacteria
refer
bacteria
resist
firstlin
antibiot
repres
less
isol
resist
secondlin
antibiot
even
rare
kadri
et
al
solut
combin
monitor
serum
level
advers
event
dialysi
nephrotox
drug
rolain
baquero
could
offer
great
potenti
treat
patient
mdr
bacterium
problem
remain
abl
routin
test
larg
panel
molecul
autom
reproduc
expens
way
lp
sb
jmr
draft
revis
manuscript
author
read
approv
final
manuscript
work
support
french
govern
invest
futur
program
manag
agenc
national
de
la
recherch
anr
fr
nation
agenc
research
refer
infect
work
support
dazur
european
fund
feder
primi
